ISSN 1016-5169 | E-ISSN 1308-4488
pdf
Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2010; 38(5): 334-340

Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure

Müjgan Tek1, Yüksel Çavuşoğlu1, Canan Demirüstü2, Alparslan Birdane1, Ahmet Ünalır1, Bülent Görenek1, Ömer Göktekin1, Necmi Ata1
1Cardiology Department, Eskisehir Osmangazi University, Eskisehir, Turkey
2Biostatistic Department, Eskisehir Osmangazi University, Eskisehir, Turkey


OBJECTIVES
Unlike traditional inotropic agents, levosimendan is thought to have a lower potential to induce arrhythmias because it does not increase intracellular calcium levels and myocardial oxygen consumption. We compared the potential effect of levosimendan and dobutamine to induce cardiac arrhythmias in patients with decompensated heart failure.

STUDY DESIGN
Fifty patients with acute decompensated heart failure (NYHA class III-IV, ejection fraction <35%) who were in need of inotropic support were randomized to dobutamine (n=25; mean age 69±10 years) or levosimendan (n=25; mean age 67.5±11.5 years) and underwent 24-hour Holter monitoring before and during inotropic infusion. Holter recordings were analyzed with respect to heart rate (HR), ventricular premature contraction (VPC), couplets of VPC, supraventricular premature contraction (SVPC), paroxysmal atrial fibrillation (PAF), and nonsustained ventricular tachycardia (NSVT).

RESULTS
Before infusions, the two groups were similar with respect to HR, VPC, couplets of VPC, SVPC, and PAF episodes, but the number of NSVT episodes was significantly higher in the levosimendan group. Heart rate and the number of VPCs increased significantly during infusions of levosimendan (p=0.036 and p<0.001, respectively) and dobutamine (for both p<0.001). Increase in couplets of VPC was significant only with dobutamine (p=0.012). The episodes of NSVT and PAF increased with levosimendan, without reaching significance. Levosimendan and dobutamine groups were similar in terms of percentage changes in arrhythmias (55±224% vs. 11±16% for VPC; 2±2.7% vs. 12±9% for couplets of VPC; 3.4±5.8% vs. 16±39% for SVPC, 0.4±2.8% vs. -2±0% for NSVT) and percentage change in total arrhythmias (41±190% vs. 18±35.4%), and the mean HR, VPC, couplets of VPC, SVPC, and episodes of NSVT and PAF (p>0.05).

CONCLUSION
Our findings suggest that levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias.

Keywords: Arrhythmias, cardiac/etiology, dobutamine/therapeutic use; electrocardiography, ambulatory; heart failure/drug therapy; pyridazines/therapeutic use/adverse effects

How to cite this article
Müjgan Tek, Yüksel Çavuşoğlu, Canan Demirüstü, Alparslan Birdane, Ahmet Ünalır, Bülent Görenek, Ömer Göktekin, Necmi Ata. Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure. Turk Kardiyol Dern Ars. 2010; 38(5): 334-340

Corresponding Author: Yüksel Çavuşoğlu, Türkiye
Manuscript Language: Turkish


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.